Tomoko Shimomura-Takimoto

Otsu, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study.

Journal: Leukemia & lymphoma

Published: March 26, 2025

Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

Journal: Cureus

Published: May 11, 2023

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.

Journal: International journal of hematology

Published: July 06, 2020

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.

Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.

Journal: British journal of haematology

Published: February 22, 2020

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib.

Journal: Infection and drug resistance

Published: February 09, 2020

Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.

Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.

Journal: Experimental hematology

Published: January 19, 2020

BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.

BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.

Journal: Cancer genomics & proteomics

Published: October 04, 2019

Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy.

Primary intraocular natural killer-cell lymphoma successfully treated using a multidisciplinary strategy.

Journal: Annals of hematology

Published: September 10, 2019

Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.

Prediction of delayed platelet engraftment after autologous stem cell transplantation for B-cell non-Hodgkin lymphoma.

Journal: Leukemia & lymphoma

Published: July 19, 2019

Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.

Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.

Journal: Annals of hematology

Published: January 07, 2019

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.

Journal: International journal of hematology

Published: November 27, 2018

A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma.

A novel method of amplified fluorescent in situ hybridization for detection of chromosomal microdeletions in B cell lymphoma.

Journal: International journal of hematology

Published: November 26, 2018

Showing 1-12 of 15

Last Updated: 09/26/2026